InveniAI
- Company typePrivate
- Founded2017
- HeadquartersGuilford, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
InveniAI firmographics
Firmographics- Name
- InveniAI
- Legal name
- InveniAI LLC
- Website
- https://inveniai.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
InveniAI industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), Translational Medicine & Biomarkers (HLAIALAF)
Keywords
Where InveniAI is headquartered
LocationHeadquarters
- HQ city
- Guilford
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
InveniAI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Strategic Collaborations with Pharma: InveniAI enters multi-year strategic collaborations with pharmaceutical companies where they receive upfront payments, development milestones, and royalties. Collaborations typically grant partners access to AlphaMeld platform for target discovery and drug development.
- Milestone Payments: Revenue generated through development and commercial milestones tied to progress of partnered drug candidates through clinical development phases.
- Royalty Payments: Ongoing royalties from successful commercialization of drug candidates identified or developed through the AlphaMeld platform for partners.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
InveniAI product offering
Product offeringCore offering
InveniAI develops and licenses the AlphaMeld AI platform, a machine-learning-based universal signal detection system that identifies novel drug targets, drug candidates, and healthcare innovations from over a decade of curated scientific, medical, chemical, and biological data. The company partners with pharmaceutical and biotech firms through multi-year strategic collaborations that generate upfront payments, development milestones, and royalties, while also advancing its own therapeutic pipeline targeting the gut-brain axis and inflammasome pathways.
Product overview
InveniAI offers a unified platform-plus-modules architecture built around AlphaMeld®, an AI- and ML-powered platform that monitors drug targets, drugs, and healthcare products and technologies. The platform integrates complex scientific, medical, chemical, and biological data to identify transformative therapeutic opportunities. The product portfolio includes the core AlphaMeld® platform, the generative AI assistant ChatAlphaMeld™ for enhanced research capabilities, and specialized modules TargetMeld™ and RxMeld™ for predictive analytics in target and drug discovery. The company leverages this technology to accelerate drug discovery programs for industry partners and advance its own therapeutic pipeline targeting gut-brain axis and inflammasome pathways for chronic inflammatory diseases.
Differentiator
Problem solved
Functional benefit
Brands
- AlphaMeld: AI-based universal signal detection platform powered by machine learning that accelerates innovation by identifying alpha signals for targets, drugs, and healthcare products and technologies. Primed with curated datasets for over a decade, it generates testable hypotheses across pharmacotherapy modalities including antibody, protein replacement, siRNA, mRNA, small molecule, cell and gene therapy, and gene-editing modalities.
- ChatAlphaMeld
- TargetMeld
- RxMeld
Products and services
- AlphaMeld AI-based universal signal detection system powered by machine learning that accelerates innovation by identifying alpha signals for targets, drugs, and healthcare products and technologies. Primed with over a decade of curated data sets, it generates testable hypotheses across pharmacotherapy modalities including antibody, protein replacement, siRNA, mRNA, small molecule, cell and gene therapy, and gene-editing modalities. Licensed to pharmaceutical and biotech partners through multi-year strategic collaborations.
- ChatAlphaMeld Generative AI Drug Discovery Assistant built on the AlphaMeld platform that integrates GPT-4, Turbo, Mixtral, Zephyr, and fine-tuned models. Provides enhanced natural language processing for rapid literature review, predictive analytics to inform clinical trial design, and AlphaMeld Knowledge Graph validation for cross-domain hypothesis verification.
- TargetMeld Predictive analytics product powered by AlphaMeld that provides comprehensive access to emerging targets for drug discovery and development.
- RxMeld Predictive analytics product powered by AlphaMeld that provides comprehensive access to emerging drug candidates and therapeutic development insights.
Quantifiable outcome
- Reduces innovation cycle by 4-5 years according to GSK partnership
- +3 more outcomes
Companies that use InveniAI
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
InveniAI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
InveniAI partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and core.
- Ono PharmaminorAI-driven Target Discovery collaboration using AlphaMeld platform.
- PRISM BioLab (Milestone)corePRISM achieved milestone by generating INVA8003, a peptidomimetic inhibitor of PYCARD - successful generation of small molecule therapeutic candidate.
- Sosei HeptarescoreMulti-target AI-powered collaboration to create transformative therapeutics for immune diseases. Combines InveniAI's validated AI-based platform with Sosei Heptares' GPCR structure-based drug design capabilities.
- ShionogicoreMulti-year multi-target drug discovery collaboration. InveniAI uses AlphaMeld to research and validate targets; Shionogi synthesizes and develops compounds for identified targets and advances select programs into research and clinical development. InveniAI eligible for up to $200 million per program for upfront payments, milestones, and royalties.
- Kyowa KirincoreExpanded collaboration (from initial 2018 partnership) leveraging AlphaMeld for novel target discovery and validation to generate a clinical pipeline of therapeutic antibodies. Kyowa Kirin selects multiple programs to advance into clinical development. InveniAI receives upfront payment, development and commercial milestones, and royalties.
- PRISM BioLabcoreCollaboration for development of therapeutic candidates for gut-related diseases impacted by Gut-Brain Axis and inflammasome activation pathways. InveniAI uses AlphaMeld to identify and validate novel targets; PRISM BioLab designs small-molecule candidates against validated targets using their proprietary platform. PRISM eligible for upfront payments, development milestones, and single-digit royalties.
- GlaxoSmithKline Consumer HealthcarecoreThree-year strategic collaboration leveraging AlphaMeld platform to capture consumer-specific innovation for GSK's internal and external R&D. The collaboration grants full access to InveniAI's AI Innovation Lab including the Consumer Healthcare Module of AlphaMeld and cross-functional expert teams. AI and ML have helped create efficiencies that shave 4-5 years off the innovation cycle.
- TB AllianceminorStrategic partnership where TB Alliance leverages AlphaMeld platform for tuberculosis drug discovery and development.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
InveniAI competitors and assessment
Company assessmentDirect peers
- Atomwise: AI-driven small molecule discovery company using structure-based deep learning models across multiple therapeutic areas; competes with AlphaMeld's small-molecule modality support.
- Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with machine learning to identify targets and advance therapeutic programs, directly comparable to InveniAI's AlphaMeld platform model.
- Exscientia: AI-focused pharma company partnering with major pharma on target identification, molecule design, and clinical translation; operates a similar partner-led, milestone/royalty revenue model as InveniAI.
- Insitro: Machine learning-driven drug discovery company combining data generation and predictive models to advance therapeutic candidates, with analogous big-pharma collaboration structures to InveniAI.
- BenevolentAI: AI-driven drug discovery company using knowledge graphs and ML to identify novel targets and indications; competes directly with InveniAI for pharma partnerships and target ID mandates.
- BioXcel Therapeutics: Public clinical-stage biopharma spun out of the same parent (BioXcel LLC) that incubated InveniAI; uses AI in drug re-innovation and is the company behind BXCL501, the Phase III AI-validated asset referenced by InveniAI.
Broad incumbents
- Schrödinger: Established computational chemistry and molecular simulation platform serving pharma R&D at scale; broader incumbent with overlapping drug-discovery AI capabilities versus InveniAI's narrower AI target-ID focus.
- Tempus Labs: Large AI-enabled precision medicine company aggregating multi-modal clinical and molecular data for pharma partners; broader incumbent with adjacent AI-for-drug-development capabilities.
Emerging players
- Iambic: Early-stage AI drug discovery company combining physics-based modeling with foundation models for chemistry; emerging direct competitor in the AI-led pharma partnership space.
- Owkin: AI biotech applying ML to patient-derived data for target discovery and clinical development across pharma; overlapping positioning with InveniAI's pharma-partnered, AI-first discovery approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
InveniAI social profiles
Digital presenceInveniAI financial estimates
Financial estimateRevenue estimate
Valuation estimate
InveniAI leadership team
Management profileNumber of profiles
Profiles6 records
InveniAI subsidiaries and ownership
Company hierarchySubsidiaries1 record
InveniAI funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InveniAI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InveniAI
What does InveniAI do?
InveniAI develops and licenses the AlphaMeld AI platform, a machine-learning-based universal signal detection system that identifies novel drug targets, drug candidates, and healthcare innovations from over a decade of curated scientific, medical, chemical, and biological data. The company partners with pharmaceutical and biotech firms through multi-year strategic collaborations that generate upfront payments, development milestones, and royalties, while also advancing its own therapeutic pipeline targeting the gut-brain axis and inflammasome pathways.
Is InveniAI a public or private company?
InveniAI is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was InveniAI founded?
InveniAI was founded in 2017. It employs 101 to 250 people.
Where is InveniAI based?
InveniAI is headquartered in Guilford, United States, in the North America region.
How does InveniAI make money?
Three revenue lines are on record. Strategic Collaborations with Pharma is the primary driver. The others are milestone Payments and royalty Payments.
Who are InveniAI's main competitors?
Direct peers on record are Atomwise, Recursion Pharmaceuticals, Exscientia, Insitro, BenevolentAI and BioXcel Therapeutics. Broad incumbents are Schrödinger and Tempus Labs. Emerging players are Iambic and Owkin.
Does InveniAI have an API?
Yes. AlphaMeld platform is accessible via the AI Innovation Lab with internal team of cross-functional experts. Contact for access: [email protected]. ChatAlphaMeld is a Generative AI Drug Discovery Assistant that integrates sophisticated AI models such as GPT-4, Turbo, Mixtral, Zephyr, and fine-tuned models. No public API documentation or developer portal identified; access appears to be enterprise/partner-facing. Developer documentation is at alphameld.com/auth?action=login.
What industry is InveniAI in?
InveniAI's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2834.